10 minutes

Tosymra® delivers migraine pain relief in as little as 10 minutes with just one spray for some patients (13% vs. 5% for placebo).*1-3

Give your patients options

Oral therapy may not be the optimal treatment for every migraine. See why Tosymra® uses the novel ingredient Intravail®.

Tosymra® achieved peak plasma concentration

8x faster than Imitrex® nasal spray4

Mean sumatriptan plasma concentration-time profile

Results from a randomized, crossover, pilot pharmacokinetic study conducted in 18 healthy adults.4 In this study, three AEs occurred with Tosymra® (vomiting, paresthesia and burning sensation in nose). Three AEs occurred with Imitrex® (sumatriptan) 20 mg nasal spray (nausea and throat irritation [two events]). All events were mild or moderate in intensity.5


Tosymra® uses the science of Intravail®

Tosymra® is the first and only triptan nasal spray to use the novel ingredient Intravail® to enhance drug absorption across the nasal mucosa.6

Controlled transient permeation of the nasal mucosa6

Intravail® is thought to facilitate paracellular absorption by transiently relaxing tight junctions, allowing drug access to systemic circulation, among other mechanisms.6-8

Nasal mucosa

Tosymra® is a sumatriptan nasal spray with mist-like administration

The safety profile of Tosymra® is generally consistent with that of subcutaneous injectable sumatriptan.


Most common adverse reactions (≥5% and > placebo) with sumatriptan injection were tingling, dizziness/vertigo, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, flushing, feeling of tightness, and numbness.

Additional common adverse reactions with Tosymra® include the local irritative symptoms of application site reaction, dysgeusia, and throat irritation.


In a 6-month open-label, repeat-dose safety study designed to assess the safety and tolerability of Tosymra® in 167 adult patients, Tosymra® was well-tolerated, with a low rate of triptan-related adverse events (TEAEs).9 Over the course of the 6-month study, 3,292 doses of Tosymra® were used to treat 2,211 migraine attacks.10

Most common TEAEs
(≥5% of subjects)
Total events
Incidence per
individual dose5,9
Application site pain* 51 (30.5%) 568 17.3%
Dysgeusia 35 (21.0%) 232 7.0%
Upper respiratory tract infection 18 (10.8%) 24 0.7%
Nasopharyngitis 12 (7.2%) 13 0.4%
Sinusitis†† 11 (6.6%) 12 0.4%
Application site reaction 9 (5.4%) 32 1.0%
  • 5 patients (3%) discontinued due to adverse events.10
  • Overall, 2.9% of doses were associated with a triptan-related TEAE.10
  • The majority of triptan-related adverse events were mild; none were severe.9

Making Migraine Our Priority

Tonix Medicines, Inc. takes pride in providing attentive customer service, having strong industry relationships and being dedicated to uninterrupted supply.

Tosymra® continues our commitment to ensure you have a variety of medication options that can address the unique needs of migraine patients.

Want more information?

Sign up today to learn more about Tosymra®.

    *All fields required.

    Privacy Policy and Authorization

    By clicking the submit button below, you consent to the use by Tonix Medicines, Inc. and its third parties of the information you have provided to periodically send you information about Tosymra® or other products and promotions.

    Tonix Medicines, Inc. and its third parties use the information you provide for legitimate business purposes only and will not sell, share, or otherwise distribute your personal information to third parties. By joining, you acknowledge that your consent to receive automated messages is not required as a condition to purchase goods and services.